CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Scinnohub Pharmaceutical Co. Ltd. has synthesized S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has disclosed pyrimidopyrazine compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
News of GSK plc’s decision to decline its option for MAT2A inhibitor IDE-397, the lead compound from a 2020 collaboration with Ideaya Biosciences Inc. sent the latter’s shares (NASDAQ:IDYA) slipping 35% to close Aug. 15 at $10.20. For Ideaya, however, which maintained that it has sufficient capital to see the program through phase II on its own, the move works out just fine.
Glaxosmithkline plc (GSK) will collaborate in three of Ideaya Biosciences Inc.’s synthetic lethality programs, MAT2A (methionine adenosyltransferase 2a), Pol Theta (polymerase theta) and Werner Helicase, in a deal that Ideaya estimated could be worth billions.
